טוען...
The 2015 CUA-CUOG Guidelines for the management of castration-resistant prostate cancer (CRPC)
Agents that have shown improvements in survival in mCRPC now include abiraterone, enzalutamide, docetaxel, cabazitaxel and radium-223. Bone supportive agents and palliative radiation continue to play an important role in the overall management of mCRPC. Given the complexity, variety and importance o...
שמור ב:
| הוצא לאור ב: | Can Urol Assoc J |
|---|---|
| Main Authors: | , , , , , , , , , , , , , |
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Canadian Medical Association
2015
|
| נושאים: | |
| גישה מקוונת: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4455631/ https://ncbi.nlm.nih.gov/pubmed/26085865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.5489/cuaj.2526 |
| תגים: |
הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|